Literature DB >> 29468974

Potentials of PKC in Cancer Progression and Anticancer Drug Development.

Suman J Deka1, Vishal Trivedi1.   

Abstract

PKC is a family of serine-threonine kinases which play crucial roles in the regulation of important signal transduction pathways in mammalian cell-biology. These enzymes are themselves regulated by various molecules that can serve as ligands to the regulatory domains and translocate PKC to membrane for activity. The role of PKC in the modulation of both proliferative and apoptotic signaling in cancer has become a subject of immense interest after it was discovered that PKC regulates a myriad of enzymes and transcription factors involved in carcinogenic signaling. Therefore, PKC has served as an attractive target for the development of newer generation of anti-cancer drugs. The following review discusses the potential of PKC to be regarded as a target for anti-cancer therapy. We also review all the molecules that have been discovered so far to be regulators/activators/inhibitors of PKC and also how far these molecules can be considered as potential candidates for anti-cancer drug development based on PKC. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Agonist; antagonists; cancer; metastasis; protein kinase C; signal transduction.

Year:  2019        PMID: 29468974     DOI: 10.2174/1570163815666180219113614

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  2 in total

1.  SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.

Authors:  Joanna R Sinnakannu; Kian Leong Lee; Shanshan Cheng; Jia Li; Mengge Yu; Siew Peng Tan; Clara Chong Hui Ong; Huihua Li; Hein Than; Olga Anczuków-Camarda; Adrian R Krainer; Xavier Roca; Steven G Rozen; Jabed Iqbal; Henry Yang; Charles Chuah; Sin Tiong Ong
Journal:  Leukemia       Date:  2020-02-12       Impact factor: 11.528

2.  PKCα is a Potentially Useful Marker for Planning Individualized Radiotherapy for Nasopharyngeal Carcinoma.

Authors:  Jing Zhang; Lu Zhang; Bowen Xie; Yumei Duan; Ying Wang; Liangfang Shen
Journal:  Cancer Manag Res       Date:  2021-03-17       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.